Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology, Inc.
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology - STAT
Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech gets EU panel nod for breast cancer drug, Health News, ET HealthWorld
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Puma Biotechnology Inc (NASDAQ:PBYI) Share Price | RNS News, Quotes, & Charts | PBYI
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
